# Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines

> **NCT02882893** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 238 (estimated)

## Conditions studied

- Crows Feet Lines

## Interventions

- **DRUG:** Clostridium Botulinum A Toxin
- **DRUG:** Clostridium Botulinum A Toxin

## Key facts

- **NCT ID:** NCT02882893
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-01
- **Final completion:** 2017-04
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2016-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882893, "Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines". Retrieved via MORVS 2026-10-08 from https://api.morvs.ai/clinical/NCT02882893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*